Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma

Yang,Jin; Liu,Peijun; Tian,Meijuan; Li,Yuyao; Chen,Wei; Li,Xu

doi:10.3892/ijo.2013.1889

Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma

Authors:
- Jin Yang
- Peijun Liu
- Meijuan Tian
- Yuyao Li
- Wei Chen
- Xu Li
View Affiliations

Affiliations: Medical Oncology Department, The First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an 710061, P.R. China, Center for Translational Medicine, The First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an 710061, P.R. China
Published online on: April 10, 2013 https://doi.org/10.3892/ijo.2013.1889
Pages: 2078-2086

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Identification of new therapeutic and prognostic biomarkers for clear cell renal cell carcinoma (ccRCC) is urgently required since most patients are in advanced stages of ccRCC at initial diagnosis and the recurrence rate is high. Differentially expressed proteins between the ccRCC cell line RLC-310 and the normal renal cell line HK-2 were identified by a comparative proteomic approach based on a protein fractionation two-dimensional (PF-2D) liquid-phase fractionation system and capillary liquid chromatography electrospray ionization mass spectrometry/mass spectrometry (LC-ESI-MS/MS). Differentially expressed proteins (n=196) were identified. Of the 13 differentially expressed proteins newly discovered in ccRCC, angiomotin (Amot) was the focus of this study since its role in ccRCC progression has been obscure. The overexpression of Amot in ccRCC tissues was confirmed by comparing Amot expression in 18 primary ccRCC tissues and adjacent normal renal tissues (ANRT) using western blot analysis. Quantitative RT-PCR using 127 ccRCC tissues revealed that high levels of Amot transcripts were associated with poor differentiation, venous invasion and decreased survival (p<0.0001, <0.05 and <0.05). Multivariate analysis indicated that Amot transcript was an independent prognostic factor for the survival of ccRCC patients (p<0.05). These data suggest that Amot may serve as a novel prognostic factor of ccRCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Drucker BJ: Renal cell carcinoma: current status and future prospects. Cancer Treat Rev. 31:536–545. 2005. View Article : Google Scholar : PubMed/NCBI
3	Fisher RI, Rosenberg SA and Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 6(Suppl 1): S55–S57. 2000.PubMed/NCBI
4	Messing EM, Manola J, Wilding G, et al: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 21:1214–1222. 2003. View Article : Google Scholar : PubMed/NCBI
5	Gonzalez LJ, Espinosa E, Garcia CI, et al: Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 31(Suppl 1): S11–S17. 2012. View Article : Google Scholar : PubMed/NCBI
6	Patard JJ, Pouessel D, Bensalah K and Culine S: Targeted therapy in renal cell carcinoma. World J Urol. 26:135–140. 2008. View Article : Google Scholar : PubMed/NCBI
7	Rathmell WK and Chen S: VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther. 8:63–73. 2008. View Article : Google Scholar : PubMed/NCBI
8	Audenet F, Yates DR, Cancel-Tassin G, Cussenot O and Roupret M: Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int. 109:1864–1870. 2012. View Article : Google Scholar : PubMed/NCBI
9	Cho IC and Chung J: Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol. 53:217–228. 2012. View Article : Google Scholar : PubMed/NCBI
10	Simpson RJ and Dorow DS: Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol. 19:S40–S48. 2001. View Article : Google Scholar : PubMed/NCBI
11	Banks RE, Craven RA, Harnden P, Madaan S, Joyce A and Selby PJ: Key clinical issues in renal cancer: a challenge for proteomics. World J Urol. 25:537–556. 2007. View Article : Google Scholar : PubMed/NCBI
12	Petricoin EF, Zoon KC, Kohn EC, Barrett JC and Liotta LA: Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 1:683–695. 2002. View Article : Google Scholar : PubMed/NCBI
13	Arsanious A, Bjarnason GA and Yousef GM: From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer. 8:202009. View Article : Google Scholar : PubMed/NCBI
14	Nogueira M and Kim HL: Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol. 26:113–124. 2008. View Article : Google Scholar : PubMed/NCBI
15	Wood SL, Rogers M, Cairns DA, et al: Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 103:101–111. 2010. View Article : Google Scholar : PubMed/NCBI
16	Yang J, Li A, Yang Y and Li X: Identification of cyclophilin A as a potential prognostic factor for clear-cell renal cell carcinoma by comparative proteomic analysis. Cancer Biol Ther. 11:535–546. 2011. View Article : Google Scholar : PubMed/NCBI
17	Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
18	Chang JT, Chen IH, Liao CT, et al: A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem. 35:591–596. 2002. View Article : Google Scholar : PubMed/NCBI
19	Kikuno R, Nagase T, Ishikawa K, et al: Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 6:197–205. 1999. View Article : Google Scholar
20	Troyanovsky B, Levchenko T, Mansson G, Matvijenko O and Holmgren L: Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol. 152:1247–1254. 2001. View Article : Google Scholar : PubMed/NCBI
21	Levchenko T, Bratt A, Arbiser JL and Holmgren L: Angiomotin expression promotes hemangioendothelioma invasion. Oncogene. 23:1469–1473. 2004. View Article : Google Scholar : PubMed/NCBI
22	Jiang WG, Watkins G, Douglas-Jones A, Holmgren L and Mansel RE: Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer. 6:162006. View Article : Google Scholar : PubMed/NCBI
23	Holmgren L, Ambrosino E, Birot O, et al: A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA. 103:9208–9213. 2006. View Article : Google Scholar : PubMed/NCBI
24	Levchenko T, Veitonmaki N, Lundkvist A, et al: Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo. FASEB J. 22:880–889. 2008. View Article : Google Scholar : PubMed/NCBI
25	Arigoni M, Barutello G, Lanzardo S, et al: A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis. 15:305–316. 2012. View Article : Google Scholar
26	Wells CD, Fawcett JP, Traweger A, et al: A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell. 125:535–548. 2006. View Article : Google Scholar
27	Aase K, Ernkvist M, Ebarasi L, et al: Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev. 21:2055–2068. 2007. View Article : Google Scholar : PubMed/NCBI
28	Yi C, Troutman S, Fera D, et al: A tight junction-associated Merlin-angiomotin complex mediates Merlin’s regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell. 19:527–540. 2011.PubMed/NCBI
29	Zhao B, Li L, Lu Q, et al: Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI
30	Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C and Hong W: Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem. 286:7018–7026. 2011. View Article : Google Scholar : PubMed/NCBI
31	Rini BI: VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr Oncol Rep. 8:85–89. 2006. View Article : Google Scholar : PubMed/NCBI
32	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
33	Hu Y, Liu J and Huang H: Recent agents targeting HIF-1alpha for cancer therapy. J Cell Biochem. 114:498–509. 2013. View Article : Google Scholar : PubMed/NCBI
34	Rathmell WK, Wright TM and Rini BI: Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther. 5:1031–1040. 2005. View Article : Google Scholar : PubMed/NCBI